M
Minoru Tanaka
Researcher at Harvard University
Publications - 11
Citations - 525
Minoru Tanaka is an academic researcher from Harvard University. The author has contributed to research in topics: Bromodomain & Protein arginine methyltransferase 5. The author has an hindex of 6, co-authored 10 publications receiving 416 citations. Previous affiliations of Minoru Tanaka include Broad Institute.
Papers
More filters
Journal ArticleDOI
MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells.
Gregory V. Kryukov,Gregory V. Kryukov,Frederick H. Wilson,Frederick H. Wilson,Jason R. Ruth,Jason R. Ruth,Joshiawa Paulk,Joshiawa Paulk,Aviad Tsherniak,Sara Marlow,Sara Marlow,Francisca Vazquez,Francisca Vazquez,Barbara A. Weir,Barbara A. Weir,Mark E. Fitzgerald,Minoru Tanaka,Minoru Tanaka,Craig M. Bielski,Craig M. Bielski,Justin M. Scott,Courtney Dennis,Glenn S. Cowley,Jesse S. Boehm,David E. Root,Todd R. Golub,Clary B. Clish,James E. Bradner,James E. Bradner,William C. Hahn,William C. Hahn,Levi A. Garraway,Levi A. Garraway +32 more
TL;DR: The discovery of cancer dependencies has the potential to inform therapeutic strategies and to identify putative drug targets and reveal PRMT5 as a potential vulnerability across multiple cancer lineages augmented by a common “passenger” genomic alteration.
Journal ArticleDOI
Design and characterization of bivalent BET inhibitors
Minoru Tanaka,Justin M. Roberts,Hyuk-Soo Seo,Amanda Souza,Joshiawa Paulk,Thomas G. Scott,Stephen L. DeAngelo,Sirano Dhe-Paganon,James E. Bradner,James E. Bradner +9 more
TL;DR: Biophysical and biochemical studies suggest MT1 is an intramolecular bivalent BRD4 binder that is over 100-fold more potent in cellular assays compared to the corresponding monovalent antagonist, JQ1.
Journal ArticleDOI
Inhibitors of emerging epigenetic targets for cancer therapy: a patent review (2010–2014)
TL;DR: This review considers patent applications for small-molecule inhibitors of selected epigenetic targets from 2010 to 2014 and includes exemplary classes of chromatin-associated epigenomic writers, erasers and readers.
Patent
Diaminopyrimidine benzenesulfone derivatives and uses thereof
TL;DR: In this article, the authors provide compounds of formula (II) (e.g., compounds of Formula (I)), and pharmaceutically compositions thereof, which are believed to be binders of brommodomains and/or bromodomain-containing proteins.
Patent
Bivalent bromodomain inhibtors and uses thereof
TL;DR: In this paper, bivalent inhibitors of BET bromodomains, such as compounds of Formulae (I), (II), (III), (IV), (V) and (VI), are presented.